Bacterial superglue generates a full-length circumsporozoite protein virus-like particle vaccine capable of inducing high and durable antibody responses by Janitzek, Christoph M et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Bacterial superglue generates a full-length circumsporozoite protein virus-like particle
vaccine capable of inducing high and durable antibody responses
Janitzek, Christoph M; Matondo, Sungwa; Thrane, Susan; Nielsen, Morten A; Kavishe,
Reginald; Mwakalinga, Steve B; Theander, Thor G; Salanti, Ali; Pedersen, Adam Frederik
Sander
Published in:
Malaria Journal
DOI:
10.1186/s12936-016-1574-1
Publication date:
2016
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Janitzek, C. M., Matondo, S., Thrane, S., Nielsen, M. A., Kavishe, R., Mwakalinga, S. B., ... Pedersen, A. F. S.
(2016). Bacterial superglue generates a full-length circumsporozoite protein virus-like particle vaccine capable of
inducing high and durable antibody responses. Malaria Journal, 15, [545]. https://doi.org/10.1186/s12936-016-
1574-1
Download date: 03. feb.. 2020
Janitzek et al. Malar J  (2016) 15:545 
DOI 10.1186/s12936-016-1574-1
RESEARCH
Bacterial superglue generates a 
full-length circumsporozoite protein virus-like 
particle vaccine capable of inducing high 
and durable antibody responses
Christoph M. Janitzek1,2†, Sungwa Matondo3†, Susan Thrane1,2, Morten A. Nielsen1,2, Reginald Kavishe3, 
Steve B. Mwakalinga3, Thor G. Theander1, Ali Salanti1,2* and Adam F. Sander1,2*
Abstract 
Background: Malaria, caused by Plasmodium falciparum, continues to have a devastating impact on global health, 
emphasizing the great need for a malaria vaccine. The circumsporozoite protein (CSP) is an attractive target for a 
malaria vaccine, and forms a major component of RTS,S, the most clinically advanced malaria vaccine. The clinical 
efficacy of RTS,S has been moderate, yet has demonstrated the viability of a CSP-based malaria vaccine. In this study, 
a vaccine comprised of the full-length CSP antigen presented on a virus-like particle (VLP) is produced using a split-
intein conjugation system (SpyTag/SpyCatcher) and the immunogenicity is tested in mice.
Methods: Full-length 3d7 CSP protein was genetically fused at the C-terminus to SpyCatcher. The CSP-SpyCatcher 
antigen was then covalently attached (via the SpyTag/SpyCatcher interaction) to Acinetobacter phage AP205 VLPs 
which were modified to display one SpyTag per VLP subunit. To evaluate the VLP-display effect, the immunogenicity 
of the VLP vaccine was tested in mice and compared to a control vaccine containing AP205 VLPs plus unconjugated 
CSP.
Results: Full-length CSP was conjugated at high density (an average of 112 CSP molecules per VLP) to AP205 SpyTag-
VLPs. Vaccination of mice with the CSP Spy-VLP vaccine resulted in significantly increased antibody titres over a course 
of 7 months as compared to the control group (2.6-fold higher at 7 months after immunization). Furthermore, the CSP 
Spy-VLP vaccine appears to stimulate production of IgG2a antibodies, which has been linked with a more efficient 
clearing of intracellular parasite infection.
Conclusion: This study demonstrates that the high-density display of CSP on SpyTag-VLPs, significantly increases the 
level and quality of the vaccine-induced humoral response, compared to a control vaccine consisting of soluble CSP 
plus AP205 VLPs. The SpyTag-VLP platform utilized in this study constitutes a versatile and rapid method to develop 
highly immunogenic vaccines. It might serve as a generic tool for the cost-effective development of effective VLP-
vaccines, e.g., against malaria.
Keywords: Virus-like particle, VLP, Pre-erythrocytic, Malaria vaccine, Circumsporozoite protein, CSP, Spycatcher, 
Spytag, Bacterial superglue, Split-intein
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Background
Malaria, caused by Plasmodium falciparum, continues 
to have a devastating impact on global health and is a 
leading cause of death in children and pregnant women 
in sub-Saharan Africa [1]. Naturally acquired immunity 
against malaria is transient and non-sterilizing. There is 
no commercially available malaria vaccine and the most 
commonly used interventions are bed nets and drug 
treatment, which are expensive and progressively inef-
fective due to drug resistance. The development of a 
vaccine against malaria has so far been hindered by the 
sheer complexity of the parasite life cycle [2, 3], antigenic 
variation [4], as well as an incomplete understanding of 
the interaction between P. falciparum and the human 
immune system [5]. Vaccines employing radiation-atten-
uated sporozoites have demonstrated strong and protec-
tive immune responses in rodents, primates, as well as 
human volunteers against malaria infection [6–9], cre-
ating a strong rationale for developing vaccines that tar-
get the pre-erythrocytic life stage. Due to economic and 
practical difficulties in relation to developing and imple-
menting a vaccine based on whole sporozoites, the focus 
has been on developing subunit vaccines using recombi-
nant sporozoite antigens. The circumsporozoite protein 
(CSP, Fig.  1a) has been identified as the immune-domi-
nant protective antigen in irradiated sporozoites and 
serves as the antigenic component in the leading malaria 
subunit vaccine candidate, RTS,S/AS01 (GlaxoSmith-
Kline) [10, 11]. Notably, recent results of a large phase III 
clinical study showed that the efficacy of the RTS,S/AS01 
vaccine was high immediately after the final vaccine dose, 
but waned quickly in parallel with the decline of vaccine-
specific IgG antibody levels. Both in infants (6–12 weeks) 
and young children (5–15  months) the vaccine efficacy 
was moderate, 37% in infants [12], and 47% in children 
[13], when measured over a period of 14 or 12 months, 
respectively.
The RTS,S vaccine is based on the hepatitis B small sur-
face antigen (HbsAg) particle displaying a truncated CSP 
antigen at a ratio of 1 CSP-fused HbsAg per 3 unfused 
HbsAg (Fig.  1b). Emerging data from the hepatitis vac-
cination programme suggest that the HbsAg particle 
induces an excellent memory B cell response, yet is inef-
fective at inducing long-lived plasma cells and sustainable 
IgG titres, as reviewed in [14]. Hence the RTS,S vaccine 
faces two major intrinsic obstacles to be an effective pre-
erythrocytic vaccine, such as low display of the antigen 
and a particle backbone that is ineffective in inducing 
long-lived plasma cells. In addition, the CSP antigen used 
in the RTS,S vaccine lacks the C-terminal region (i.e. 
excluding important T cell epitopes) as well as excludes 
a large portion of the central NANP repeat region (i.e. 
excluding B cell epitopes). Several other studies have 
indicated these epitopes are potentially important for 
induction of a protective immune response [15–17]. 
However, the partial protective effect of the RTS,S vac-
cine demonstrates the viability of a CSP-based malaria 
vaccine and further improvements of the vaccine may 
improve its clinical efficacy.
There is clear evidence that an ordered, repetitive and 
dense organization of epitopes, displayed on a rigid sur-
face (e.g. a virus capsid) and not a lipid-based virus-like 
Fig. 1 Graphic representation of native Plasmodium falciparum CSP compared to RTS,S and the recombinant CSP. a Native P. falciparum circum-
sporozoite protein (CSP); b Recombinant CSP construct used in the RTS,S vaccine; c Recombinant full-length CSP construct used in present study. 
The full-length CSP sequence (amino acid 25–383) comprising the entire repeat sequence (38 NANP B cell epitopes) as well as T cell epitopes 
(CD4+ and CD8+) mapped in the N- and C-terminus, was genetically fused at the C-terminus to SpyCatcher
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particle (VLP) (e.g. HbsAg VLPs) leads to induction of 
strong and durable antibody responses [18, 19]. Recent 
studies have shown that vaccine antigens presented on 
VLP platforms effectively induce high titred antibody 
responses against poorly immunogenic antigens [20, 
21]. One of these studies utilizes a split-intein (SpyTag/
SpyCatcher) conjugation system to covalently attach 
antigens on the surface of rigid Acinetobacter phage 
AP205 VLPs. In brief, the AP205 VLPs were modified 
to present one SpyCatcher, one SpyTag or two SpyTag 
per VLP subunit. By modifying antigens to include the 
corresponding binding tag (SpyTag or SpyCatcher) and 
mixing these with the Spy-VLPs, the antigen is attached 
to the surface of the rigid VLPs via a covalent bond 
formed between the SpyTag and the SpyCatcher and is 
directionally displayed at high density [21]. In the pre-
sent work, the Spy-VLP platform is used to facilitate 
directional, high-density display of a full-length CSP 
construct (Fig. 1c) covalently attached to the surface of 
AP205 SpyTag-VLPs. To evaluate the VLP-display effect, 
the immunogenicity of the CSP-SpyCatcher:SpyTag-VLP 
(CSP Spy-VLP) vaccine was tested against a control vac-
cine consisting of unconjugated monomeric CSP antigen 
and untagged AP205 VLPs by immunization of BALB/c 
mice.
Methods
Design, expression and purification of Spy‑AP205 VLPs
Acinetobacter phage AP205 Spy-VLPs, displaying one 
SpyTag per VLP subunit, were designed as previously 
described [21]. In brief, the gene encoding the major 
AP205 coat protein (Gene ID: 956335) was fused at the 
N-terminus to the SpyTag peptide sequence (AHIVM-
VDAYKPTK) along with a flexible linker. The VLP were 
expressed in Escherischia coli One Shot® BL21 Star™ 
(DE3) cells (Thermo Scientific) cells and purified via an 
Optiprep™ (Sigma) step (23, 29 and 35%) gradient.
Design, expression and purification of HIS‑CSP‑SpyCatcher 
antigen
The CSP antigen, comprising amino acids 25–383 (i.e. 
excluding the N-terminal signal peptide and the C-ter-
minal GPI-anchor) of the native 3D7 sequence (Gene 
ID: 814364), was designed with a hexa-histidine purifi-
cation tag (HIS) at N-terminus and the SpyCatcher [22] 
at the C-terminus. A Glycine–Glycine–Serine linker was 
inserted between the CSP and the SpyCatcher sequence. 
The HIS-CSP-SpyCatcher gene sequence was finally 
modified to contain a BamHI and NotI restriction site 
at the N- and C-terminus, respectively, and was codon-
optimized for and expressed in Trichoplusia ni insect 
cells, as described previously [21, 23].
Electron microscopy
An aliquot of the CSP Spy-VLP vaccine was adsorbed 
to 200-mesh mica carbon-coated grids and negatively 
stained with 2% phosphotungstic acid (pH  =  7.0). The 
VLPs were analyzed with an accelerating voltage of 80 kV, 
using a CM 100 BioTWIN electron microscope (Phillips, 
Amsterdam). An Olympus Veleta camera was utilized to 
obtain photographic records and particle sizes were esti-
mated using ImageJ.
Formulation of CSP Spy‑VLP vaccine
Purified HIS-CSP-SpyCatcher antigen and AP205 Spy-
VLP were mixed at a 1.5:1 (antigen per VLP subunit) 
molar ratio and incubated overnight at 4  °C in a conju-
gation buffer (PBS, 0.2% Polysorbate 80, pH 7.2). SDS-
PAGE densitometric analysis was used to determine 
number of VLP monomer subunits that had been con-
jugated to CSP via the SpyTag/SpyCatcher interaction. 
Specifically, this amount was assessed by dividing the 
protein band intensity value of VLP subunit protein band 
prior to the reaction with antigen (Fig.  2a, lane 1) with 
the equivalent protein band intensity value after reaction 
with antigen (Fig. 2a, lane 3, bottom), and multiplied by 
100. This percentage was multiplied by 180 (total number 
of AP205 subunits per VLP). The antigen concentration 
was adjusted to 5 µg antigen per 100 µl by dilution with 
PBS buffer (pH 7.2). One hour prior to immunizations, 
Alhydrogel (2%) (Statens Serum Institut, Copenhagen, 
Denmark) was added to a final concentration of 2 mg/ml 
aluminum hydroxide. The control vaccine was prepared 
in a similar way except using untagged VLPs instead of 
Spy-VLPs.
Mouse immunization
Eight-weeks old, female BALB/c mice (Taconic, Den-
mark) were immunized by intramuscular injection with 
100  µl vaccine (corresponding to a dose of 5  μg of CSP 
per mouse per immunization in both the CSP Spy-VLP 
vaccine group and the control group) on days 0, 14 and 
28. Immune serum was collected on days 14, 28, 42, 148, 
192, and 212.
Antibody response measured by standard ELISA
Measurement of serum immunoglobulin (Ig) levels was 
done by standard enzyme-linked immunosorbent assay 
(ELISA) as described previously [21], using 96-well 
plates (Nunc MaxiSorp) coated with 0.1  µg recombi-
nant CSP protein (no SpyCatcher) per well. The Serum 
Ig endpoint titres were determined by applying a cut-off 
of OD490 = 0.2. In addition, the geometric means of the 
titres were calculated on all measured days and the fold-
increase in titres (VLP vaccine group/control vaccine 
Page 4 of 9Janitzek et al. Malar J  (2016) 15:545 
group) was determined. The statistical analysis was per-
formed by a non-parametric, two tailed, Mann–Whitney 
Rank Sum Test, with statistical significance being defined 
at threshold P < 0.05.
Determination of serum IgG subclass profiles
IgG sub-class profiling of anti-CSP mouse sera was per-
formed according to the above described standard ELISA 
protocol and as described recently [21].
Results
Development and characterization of a VLP‑based CSP 
vaccine
The full-length CSP sequence, comprising the entire 
repeat sequence (38 NANP B cell epitopes) as well as T 
cell epitopes (CD4+ and CD8+) mapped in the N- and 
C-terminus, was genetically fused at the C-terminus 
to the SpyCatcher (Fig.  1c). The fusion construct was 
expressed in baculovirus transfected insect cells, and 
0.5  mg pure (>85%) monomeric antigen was obtained 
following purification by immobilized metal affinity chro-
matography and size-exclusion chromatography (Fig. 2a, 
lane 2).
Mixing and incubation of purified CSP-SpyCatcher 
antigen with Spy-VLPs was done at a 1.5:1 molar ratio 
(antigen per VLP subunit), respectively. The Spytag/Spy-
catcher conjugation should result in exhaustion of both 
protein components in the reaction [24]. The fact that 
there was a residual, non-conjugated Spy-VLP band on 
the SDS-page gel (Fig. 2a, lane 3, bottom) indicated that 
steric hindrance may prevent any further conjugation of 
CSP on the fully, densely covered particle, causing not 
all VLP subunits to be conjugated with an antigen. The 
densitometric analysis revealed that there was an aver-
age of 112 CSP antigens per VLP (Fig. 2a). The final vac-
cine did contain excess non-conjugated CSP, as it was 
deemed that this, if anything, would only pose a negative 
contribution to the immune response and would thus not 
introduce a bias favouring the VLP display effect (Fig. 2a, 
lane 3).
Fig. 2 Characterization of a virus-like particle-based CSP vaccine. a Reduced SDS-PAGE gels loaded with AP205 SpyTag-VLPs (lane 1), CSP-
SpyCatcher (lane 2) and the CSP Spy-VLP vaccine (lane 3), demonstrating that SpyCatcher-CSP has been covaltly conjugated to the AP205 capsid 
protein. Three protein bands formed following the reaction of SpyTag-VLPs with SpyCatcher-CSP. The bands correspond to the size of the CSP-VLP 
capsid protein conjugate (89 kDa) (lane 3 top), uncoupled CSP vaccine antigen (theoretical size 52 kDa—however it appears as 72 kDa on the SDS 
gel) (lane 3 middle) and unconjugated SpyTag-VLP capsid protein (16.5 kDa) (lane 3 bottom). Densitometric analysis comparing the protein band 
intensity of in lane 1 with the bottom band in lane 3 revealed that an average of 112 CSP-SpyCatcher antigens have been covalently attached per 
VLP. b Transmission electron microscopy of the CSP Spy-VLP vaccine (i.e., CSP-SpyCatcher covalently attached to SpyTag-VLP). CSP Spy-VLP samples 
were placed on carbon, adsorbed to a grid and negatively stained with 2% phosphotungstic acid. The large image reveals uniformly distributed, 
non-aggregated particles of approximately 49 nm. The bottom left images show a zoomed-in CSP Spy-VLP (bottom) compared to an unconjugated 
AP205 Spy-VLP (top)
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Transmission electron microscopy revealed a homog-
enous population of non-aggregated antigen-VLP com-
plexes with an estimated size of 49  nm (Fig.  2b). The 
estimated diameter of the CSP Spy-VLP, moreover, 
appears bigger compared to unconjugated Spy-VLP, with 
an estimated size of 30 nm (Fig. 2b, bottom left images), 
indicating the presence of conjugated antigen on the sur-
face of the Spy-VLPs.
Immunogenicity of the CSP Spy‑VLP vaccine
The immunogenicity of the Spy-VLP based CSP vac-
cine, formulated with aluminum hydroxide adjuvant, 
was assessed by evaluation of vaccine-induced humoral 
responses in mice. Specifically, BALB/c mice were immu-
nized intramuscularly on days 0, 14 and 28 and anti-CSP 
Ig titres were subsequently measured by ELISA in sera 
obtained at days 14, 28, 42, 148, 192, and 212 (Fig. 3). At 
days 14 and 28 anti-CSP Ig titres were significantly higher 
in mice receiving the CSP Spy-VLP vaccine compared to 
mice immunized with the unconjugated control vaccine 
(P < 0.02). At day 42 there was no statistically significant 
difference (P = 0.058) in the level of anti-CSP Ig between 
the two groups. However, measurement of anti-CSP Ig 
titres at days 148, 192 and 212 again showed significantly 
higher anti-CSP Ig titres in CSP -VLP immunized mice 
(P = 0.01, day 148 and P = 0.03, days 192 and 212).
Throughout this study, the geometric means of the CSP 
Spy-VLP vaccine group were higher compared to the 
control vaccine-immunized group (Fig.  4). This corre-
sponds to a 5.6-, 6.2-, 2-, 3-, 2.6-, and 2.6-fold increase in 
geometric mean titres in the CSP Spy-VLP vaccine group 
on days 14, 28, 42, 148, 192, and 212, respectively. At day 
148 and forth the geometric mean titre appeared to reach 
a plateau in both immunization groups.
Subclass profiling of vaccine‑induced IgG
The relative proportion of IgG subclasses elicited in 
mice immunized with the CSP Spy-VLP vaccine and the 
Fig. 3 CSP-specific IgG levels in mice after immunization with soluble or Spy-VLP displayed CSP antigen at a day 14, b day 35, c day 42, d day 148, 
e day 192 and f day 212 after first immunization. CSP-specific IgG levels (OD ELISA) in serum from mice (n = 6 CSP Spy-VLP group, n = 5 control 
vaccine group) immunized with a CSP Spy-VLP vaccine (filled circles) or with a control vaccine consisting of soluble CSP mixed with untagged AP205 
VLPs (open squares). Both vaccines were formulated using aluminum hydroxide adjuvant. Mice were immunized on days 0, 14 and 42. Differences in 
titres between vaccination groups were analysed using OD cut-off 0.2 and Mann–Whitney Rank Sum test; day 14 (P = 0.0169), day 28 (P = 0.0109), 
day 42 (P = 0.0578), day 148 (P = 0.0116), days 192 and 212 (P = 0.0316)
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unconjugated control vaccine were compared, as previ-
ously described [21]. Measurements were performed on 
sera obtained at days 14 and 42 (Fig.  5). Whereas IgG1 
was the dominant IgG subclass in all analysed sera there 
were a significantly increased proportion of anti-CSP 
IgG2a antibodies in mice immunized with the CSP Spy-
VLP vaccine compared to the control group. At day 42 
the VLP-immunized group showed a (not statistical sig-
nificant) tendency to produce more IgG2b. The IgG3 
subclass was nearly absent in all analysed sera.
Discussion
The ultimate goal of active vaccination is to induce 
prolonged, preferably life-long, protective immune 
responses, and the main effector mechanism of most 
prophylactic vaccines is the generation of protective 
antibodies [25]. Humoral memory depends on two lay-
ers of defence: (1) memory B cells that are able to rapidly 
reactivate to produce antibodies upon antigen exposure; 
and, (2) pre-existing protective antibodies secreted by 
long-lived plasma cells [26]. In the context of designing 
a malaria vaccine to prevent liver infection by the tran-
sient sporozoite form of the parasite, sufficient titres of 
circulating antibodies to protect from disease are likely 
required [27]. However, successful induction and per-
sistence of long-lived plasma cells remains a chief chal-
lenge in modern vaccine development and has generally 
not been achieved using simple subunit vaccines [28]. 
Remarkably, the licensed Human Papillomavirus (HPV) 
vaccines are able to induce stable antibody titres after a 
single immunization [19], which has been ascribed to the 
ordered, repetitive and dense display of surface epitopes 
offered by the rigid icosahedral L1 VLPs. In contrast, the 
hepatitis B vaccine lacks the ability to induce durable 
antibody titres, even after a prime-boost-boost regimen 
and protection seems, in this case, to depend on memory 
B cells rather than on long-lived plasma cells [14, 29, 30]. 
The HBV vaccine is composed of the HBsAg, presented, 
at low density (100–120 HBsAg per VLP), on the sur-
face of non-rigid lipid particles [31, 32], and it has been 
proposed that HBV particles represent a sub-optimal 
Fig. 4 Development of geometric mean titres over time. The geo-
metric mean titres were calculated for the CSP Spy-VLP vaccine group 
(filled circles) and the control vaccine group (open squares) at meas-
ured days (14, 28, 42, 148, 192, and 212) and plotted on a log-scale. 
Both immunization groups appear to reach a plateau from day 148 
and onward. The titre plateau of the CSP Spy-VLP immunized group is 
2.6-fold increase higher compared to the titre of the control vaccine 
group at days 192 and 212
Fig. 5 Anti-CSP IgG subclass profiling performed at a 14 days and b 42 days after first immunization. The proportion of anti-CSP IgG1, IgG2a, IgG2b 
and IgG3 in sera, obtained at day 14 and 42, relative to the total vaccine-induced IgG response in vaccinated mice (n = 6 for CSP-VLP vaccinated 
group and n = 5 for soluble CSP vaccine group). Mann–Whitney Rank Sum test was used for statistical comparisons
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virus-like epitope display compared to HPV L1 VLPs 
[33]. Accordingly, since it appears that the RTS,S vaccine 
is protective only while antibodies are circulating, HBsAg 
VLPs (i.e., the hepatitis B vaccine) are likely a sub-optimal 
platform for displaying the CSP antigen. On that basis it 
seemed plausible that a vaccine presenting the full-length 
CSP at high density on the surface of a rigid particle plat-
form (i.e., resembling the HPV L1 VLP epitope display) 
would enhance the quality, magnitude and breadth of 
protective antibody and T-cell responses. To this end, 
a recent study reported on the development of a Spy-
VLP display platform, enabling uni-directional presen-
tation of large antigens at high density on the surface of 
rigid AP205 bacteriophage VLPs, and demonstrated the 
capacity of the platform to induce high-titred, functional, 
anti-malaria antibodies [21].
The full-length CSP-SpyCatcher antigen construct 
expressed well in baculovirus transfected insect cells and 
was compatible with the SpyTag/SpyCatcher VLP conju-
gation system, i.e., antigen:VLP complexes did not tend 
to aggregate and precipitate as sometimes occurs during 
the SpyTag/SpyCatcher-mediated, antigen-VLP conju-
gation reaction [21]. The estimated number of antigens 
required to cover the VLP surface matched what would 
be expected based on the size of the CSP-SpyCatcher pro-
tein (53 kDa) [21]. Compared to previously tested CSP-
based VLP vaccines, the average antigen display capacity 
of the CSP Spy-VLPs is three to four times higher [34]. 
This may constitute a crucial difference as epitope density 
is an important factor for B cell activation [35, 36].
By testing the CSP Spy-VLP vaccine against a con-
trol vaccine containing SpyCatcher-CSP antigen and 
untagged AP205 VLPs it was possible to directly meas-
ure the VLP display-effect. Measurement of vaccine-
induced IgG in sera from immunized mice showed that 
the VLP display gave rise to a significantly higher anti-
CSP IgG titres after the first two immunizations, which 
was again the case after 5–6 months. When analysing the 
geometric mean titres over time, both in the CSP Spy-
VLP-immunized group as well as the control group, the 
antibody titres plateau after 5–6 months. However, the 
level of the CSP Spy-VLP-induced antibody titre plateau 
is moderately, yet significantly higher (2.6-fold increase) 
compared to the control group. These results indicate 
that the Spy-VLP display of the CSP antigen trigger a 
more efficient induction of long-lived plasma cells.
Production of AP205 VLPs in E. coli result in encap-
sidation of host cell RNA, which can pose an adjuvant 
effect via TLR 7 and 8. Besides, contaminating endo-
toxin was not removed from the VLP preparations. It is 
thus feasible that bacterial RNA and/or endotoxins have 
affected the humoral responses induced by the Spy-VLP 
and unconjugated control vaccine which could partly 
explain why the control vaccine, albeit to a lower degree, 
also managed to induce a long-lasting response.The over-
all IgG isotype profile showed a predominant induction 
of IgG1 in both test groups, although there was a statisti-
cally significant increase in the level of induced anti-CSP 
IgG of the 2a subclass in VLP-immunized mice at both 
measured days. Whether this finding possesses any bio-
logical significance remains to be tested. However, the 
IgG2a subclass has previously been linked with more 
efficient clearing of intracellular parasites [37, 38] and 
anti-CSP IgG2a antibodies have been associated with 
protection against transgenic sporozoite challenge in 
mice [39].
The antigen used in the RTS,S vaccine is an N-termi-
nally truncated CSP sequence fused to the HBsAg and 
co-expressed with unfused HBsAg in yeast cells [40, 41]. 
Since the N-terminal domain of CSP represents a target 
of protective immunity [16] the N-terminally truncated 
antigen design may not be optimal [42]. In this study 
the novel Spy-VLP platform was employed to facilitate 
virus-like display of a full-length recombinant CSP anti-
gen, which in contrast to previous multivalent displayed 
CSP constructs [34, 43–45] contains all 38 NANP repeat 
epitopes of the native sequence as well as important T- 
and B-cell epitopes mapped to the N-terminal region 
[46–48].
Conclusion
The CSP Spy-VLP vaccine appears to improve the 
response against the CSP protein measured on param-
eters potentially important for protection. The high-
density directional display of full-length CSP on the 
surface of rigid AP205 Spy-VLPs resulted in significantly 
increased levels of anti-CSP antibody responses in vacci-
nated mice over the course of 7 months. Furthermore, the 
VLP-display seemed to cause an increased induction of 
IgG2a antibodies, which have been associated with effi-
cient clearing of intracellular parasite infection. Studies 
to compare this vaccine to RTS,S head-to-head, employ-
ing extrinsic adjuvants, may help decide on further clini-
cal development. Finally, this study further supports the 
use of the Spy-VLP system as a versatile, cost-effective, 
and rapid method to develop highly immunogenic vac-
cines e.g. against malaria.
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